Sign up Australia
Proactive Investors - Run By Investors For Investors

Benitec Biopharma Ltd has Hepatitis B success with treatment

Benitec Biopharma Ltd has Hepatitis B success with treatment

Benitec Biopharma Ltd (ASX:BLT; NASDAQ:BNTC) should gain a boost today as its Hepatitis B therapy has been seen to reduce the virus (HBV) by 98.5% in a mice study.

The in vivo study assessed the activity of BB-HB-331 treatment in the PhoenixBio (PXB) mouse model and demonstrated robust and durable suppression of HBV in vivo following a single administration.

Benitec's ddRNAi technology is a combination of gene silencing using RNA interference coupled with the long term therapeutic potential of gene therapy.

Once infected with HBV, mice were treated with a one time systemic injection of BB-HB-331. Weekly assessment of serum antigen levels, HBV viral proteins and extracellular HBV DNA were conducted for the duration of the 56 day study.

The key findings in this study were that a single BB-HB-331 treatment reduced serum HBV DNA by 1.83 logs, equivalent to 98.5% elimination of circulating HBV.

The in vivo experiment validates the BB-‐HB-331 in vitro findings previously observed in human hepatocytes isolated from the PXB mouse model which was announced on 7 December 2015.

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.




Register here to be notified of future BLT Company articles
View full BLT profile

Benitec Ltd. Timeline

August 18 2015
November 11 2014
February 24 2014

Related Articles

Concept of a DNA strand
September 13 2016
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making incredible advances altering the inner workings of the human body to tackle deadly diseases.
April 05 2016
If the market worked as perfectly as its more rabid advocates insist, we wouldn’t have attractive anomalies such as Synairgen..
July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”

© Proactive Investors 2016

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.